Abstract Details

Treatment options, which include plasmapheresis, IVIg, steroids, immunosuppressants, or a combination of these and their effectiveness in reducing overall mortality remain a question of high interest in studying the outcomes of CIDP.

To investigate the effect on mortality of different treatments of chronic inflammatory demyelinating polyneuropathy (CIDP).

We used the New York State Planning and Research Cooperation (SPARCS) database to retrospectively collect all patients with CIDP from 1998-2018. ICD 9 and 10 codes were used to identify comorbidities. Mortality data was collected using discharge status as either expired or sent to hospice. Multivariate analysis with binary logistic regression adjusted for comorbidities, gender, and age. Comorbidities included type 2 diabetes, hypertension, heart failure, COPD, Parkinson’s disease, multiple sclerosis, autoimmune hypothyroidism, pneumonia, and a multitude of cardiovascular diseases were assessed from the date of diagnosis. Pearson Chi Squared test was used to test for significance.

CIDP patients with a history of treatment with plasmapheresis, steroids, immunosuppressants, IVIg or a combination at any time, when confounding for all comorbid conditions, gender and age did not significantly affect mortality when compared to patients who did not. Work is in progress for subgroup analysis and identifying other risk factors for mortality including hospital admission and socioeconomic status.